Snapshot from Sep 23, 2026 at 07:00 UTC. For live data and tracking: View Live
Accidents Ebola outbreak

DR Congo Ebola Outbreak Vaccine Trial

Analysis based on 265 articles · First reported Aug 13, 2026 · Last updated Sep 21, 2026

Sentiment
-20
Attention
4
Articles
265
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The Ebola outbreak in the DRC has limited direct impact on global financial markets, but it poses risks to regional stability and could affect commodity prices if it disrupts mining operations in eastern Congo. Pharmaceutical companies involved in vaccine development, such as Merck and Moderna, may see increased attention and potential revenue opportunities, though the overall market impact remains contained.

pharmaceuticals healthcare humanitarian aid

The Democratic Republic of the Congo is battling its worst-ever Ebola outbreak, caused by the rare Bundibugyo species, which has no approved vaccine or treatment. The outbreak was declared in mid-May 2026 and has since spread to seven provinces, with over 7,500 confirmed cases and more than 3,600 deaths reported as of late September. The World Health Organization has warned the outbreak remains out of control and is on track to surpass the 2014-2016 West Africa epidemic. In response, a vaccine trial using Merck's Ervebo vaccine, which is licensed for the Zaire strain, has begun in Ituri province, targeting frontline health workers. The trial aims to assess the vaccine's efficacy against Bundibugyo. Other vaccine candidates from Moderna and the University of Oxford are also under development. The response faces significant challenges, including insecurity from armed groups like the March 23 Movement, attacks on health workers, a health workers' strike, and funding shortages. The World Food Programme has called for food assistance, while the United Nations and other agencies have appealed for increased international support. The outbreak has spread to new provinces, including South Ubangi, raising concerns of regional spillover into neighboring countries such as Uganda, Burundi, the Central African Republic, and South Sudan.

98 Democratic Republic of the Congo reported 600 deaths
90 World Health Organization assessed risk
90 Merck Group provided Ervebo vaccine Democratic Republic of the Congo
90 Democratic Republic of the Congo reported deaths surpassing
90 Democratic Republic of the Congo passed 7,000 cases
88 United Nations appealed for funding
88 Democratic Republic of the Congo began vaccinating healthcare staff
87 United Nations appealed for funding
85 Democratic Republic of the Congo reported 7,258 cases
84 Moderna developed vaccine candidate
82 Democratic Republic of the Congo spread to South Ubangi
+ 143 more actions View on Dashboard
cnt
The DRC is the epicenter of the outbreak, facing a severe public health crisis that strains its healthcare system and economy. The outbreak has spread to seven provinces, with over 7,500 cases and 3,600 deaths, and the government is leading the response with international support.
Importance 100.0 Sentiment -30.0
govactor
Provides official case and death data; leads vaccination campaign and response efforts.
Importance 90.0 Sentiment -50.0
ngo
The WHO is coordinating the international response, declaring the outbreak a public health emergency and overseeing vaccine trials. It has warned the outbreak is far from over and requires sustained funding and resources.
Importance 90.0 Sentiment 10.0
loc
Democratic Republic of the Congo — Ituri Province is the epicenter of the outbreak, with the highest number of cases and deaths. The region's insecurity and weak infrastructure complicate the response and exacerbate the crisis.
Importance 80.0 Sentiment -60.0
govactor
Africa CDC is providing technical support and coordinating with the DRC government, warning that the outbreak is not yet under control and is spreading beyond its epicenter.
Importance 80.0 Sentiment 5.0
stock
Manufacturer of Ervebo vaccine, which is being used off-label and in trials; potential for expanded use and revenue.
Importance 70.0 Sentiment 40.0
alliance
The UN is mobilizing a broad humanitarian response, with the Secretary-General calling for urgent action and additional funding of $1.1 billion to combat the outbreak.
Importance 70.0 Sentiment 0.0
stock
Merck's Ervebo vaccine is being used in the DRC outbreak response and a clinical trial to assess its efficacy against Bundibugyo. The company may benefit from increased demand and positive publicity.
Importance 70.0 Sentiment 20.0
per
UN Secretary-General publicly appeals for funding and condemns 'indifference' to the outbreak.
Importance 60.0 Sentiment 10.0
ngo
The WFP is providing food assistance to affected communities, emphasizing that hunger undermines efforts to contain the virus. It has appealed for increased international funding.
Importance 60.0 Sentiment 0.0
per
WHO Director-General Tedros is a key figure in the international response, calling for scaled-up efforts and funding.
Importance 60.0 Sentiment 0.0
ngo
Funds research to test cross-protection of existing vaccines against Bundibugyo virus.
Importance 55.0 Sentiment 0.0
ngo
Reports attacks on volunteers and ambulances, with 12 volunteers injured in 11 violent incidents since May, hampering response.
Importance 50.0 Sentiment -5.0
ngo
Mobilizes influencers and religious leaders for awareness campaigns to combat misinformation.
Importance 50.0 Sentiment 0.0
ngo
MSF has opened a new treatment center in Beni, North Kivu, to improve response in one of the hardest-hit areas.
Importance 50.0 Sentiment 0.0
+ 56 more entities View on Dashboard
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.